Concepedia

David Sperandio

DS

Statistics

Publications

22

Citations

961

H-Index

15

Active since

1995

Affiliations

Gilead Sciences (United States)(Current)

University of Zurich

Zurich University of Teacher Education

ID Genomics (United States)

Theranostics (New Zealand)

David Sperandio is an author at Gilead Sciences (United States) specializing in medicinal chemistry, pharmacology, and drug discovery.

Publications per year

1995–2022

22

Publications

22

Discovery of an Oral Respiratory Syncytial Virus (RSV) Fusion Inhibitor (GS-5806) and Clinical Proof of Concept in a Human RSV Challenge Study

Richard L. Mackman, Michael Sangi, David Sperandio et al. · Journal of Medicinal Chemistry · 2015 · 125 citations

, , +17

Synthesis of 3,5-disubstituted-1,2,4-oxadiazoles using tetrabutylammonium fluoride as a mild and efficient catalyst

Anthony R. Gangloff, Joane Litvak, Emma Shelton et al. · Tetrahedron Letters · 2001 · 121 citations

, , +7

A New and Selective Catalyst for the [5 + 2] Cycloaddition of Vinylcyclopropanes and Alkynes

Paul A. Wender, David Sperandio · The Journal of Organic Chemistry · 1998 · 117 citations

, , +8

The Structure of the Extracellular Region of Human Hepsin Reveals a Serine Protease Domain and a Novel Scavenger Receptor Cysteine-Rich (SRCR) Domain

John R. Somoza, Joseph D. Ho, Christine Luong et al. · Structure · 2003 · 85 citations · Full text

, , +12

Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle

Richard L. Mackman, Victoria A. Steadman, David K. Dean et al. · Journal of Medicinal Chemistry · 2018 · 78 citations · Full text

, , +17

1–5 of 22